Cargando…

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants

OBJECTIVES: The study aimed to compare the immunogenicity and safety of fractional (half) third doses of heterologous COVID-19 vaccines (AZD1222 or BNT162b2) to full doses after the two-dose CoronaVac and when boosting after three different extended intervals. METHODS: At 60-<90, 90-<120, or 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niyomnaitham, Suvimol, Jongkaewwattana, Anan, Meesing, Atibordee, Pinpathomrat, Nawamin, Nanthapisal, Sira, Hirankarn, Nattiya, Siwamogsatham, Sarawut, Kirdlarp, Suppachok, Chaiwarith, Romanee, Lawpoolsri, Saranath, Phanthanawiboon, Supranee, Thitithanyanont, Arunee, Hansasuta, Pokrath, Chaiyaroj, Sansanee, Pitisuttithum, Punnee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867652/ https://www.ncbi.nlm.nih.gov/pubmed/36682680 http://dx.doi.org/10.1016/j.ijid.2023.01.022

Ejemplares similares

2238. Immunogenicity and safety of four- vs. three-standard doses HBV vaccination in HIV-infected adults with isolated anti-HBc antibody
por: Laksananun, Nattinee, et al.
Publicado: (2018)

Comparison of Immunogenicity and Safety of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: A Randomized, Controlled Trial
por: Chaiklang, Kanokporn, et al.
Publicado: (2013)

2231. Long-Term Immunogenicity of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: An Extension of a Randomized Controlled Trial
por: Chaiwarith, Romanee, et al.
Publicado: (2018)

Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial
por: Muangnoicharoen, Sant, et al.
Publicado: (2023)

Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody
por: Laksananun, Nattinee, et al.
Publicado: (2019)

Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update
por: Sripongpun, Pimsiri, et al.
Publicado: (2022)

A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
por: Nanthapisal, Sira, et al.
Publicado: (2022)

Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
por: Intapiboon, Porntip, et al.
Publicado: (2021)

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022)

Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial
por: Chaiwarith, Romanee, et al.
Publicado: (2019)

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
por: Kaewdech, Apichat, et al.
Publicado: (2022)

A two-arm analysis of the immune response to heterologous boosting of inactivated SARS-CoV-2 vaccines
por: Nithichanon, Arnone, et al.
Publicado: (2023)

T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
por: Sophonmanee, Ratchanon, et al.
Publicado: (2022)

Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
por: Sripongpun, Pimsiri, et al.
Publicado: (2023)

Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model
por: Pinpathomrat, Nawamin, et al.
Publicado: (2021)

Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine
por: Chaiwarith, Romanee, et al.
Publicado: (2023)

Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
por: Singhatiraj, Ekachai, et al.
Publicado: (2021)

Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report
por: Intapiboon, Porntip, et al.
Publicado: (2023)

Immunogenicity, Immune Dynamics, and Subsequent Response to the Booster Dose of Heterologous versus Homologous Prime-Boost Regimens with Adenoviral Vector and mRNA SARS-CoV-2 Vaccine among Liver Transplant Recipients: A Prospective Study
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2022)

Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2
por: Seephetdee, Chotiwat, et al.
Publicado: (2021)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Hepatitis B Vaccination Induced TNF-α- and IL-2-Producing T Cell Responses in HIV− Healthy Individuals Higher than in HIV+ Individuals Who Received the Same Vaccination Regimen
por: Chawansuntati, Kriangkrai, et al.
Publicado: (2018)

Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations
por: Niyomnaitham, Suvimol, et al.
Publicado: (2023)

The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization
por: Thotsiri, Sansanee, et al.
Publicado: (2022)

Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis
por: Soe, Kay Khine, et al.
Publicado: (2023)

Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022)

Phenotypic and functional changes of T cell subsets after CoronaVac vaccination
por: Phoksawat, Wisitsak, et al.
Publicado: (2022)

Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine
por: Stylianou, Elena, et al.
Publicado: (2018)

1565. Lymphocyte Subsets as Predictors of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation
por: Meesing, Atibordee, et al.
Publicado: (2018)

Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand
por: Chaiwarith, Romanee, et al.
Publicado: (2016)

Vaccine dosing controversy
por: Wilson, Clare
Publicado: (2021)

Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines
por: Luna-Casas, Gerardo, et al.
Publicado: (2018)

1690. Risk Factors of Invasive Aspergillosis in Systemic Lupus Erythematosus Patients
por: Kunawathanakul, Sithichai, et al.
Publicado: (2019)

218. Development of a Simple Score for Diagnosis Melioidosis
por: Khaejawat, Kanjana, et al.
Publicado: (2023)

286. Hepatitis B Vaccine Compliance: Comparing 2-Dose and 3-Dose Vaccines
por: Bruxvoort, Katia, et al.
Publicado: (2019)

Identification of antigens presented by MHC for vaccines against tuberculosis
por: Bettencourt, Paulo, et al.
Publicado: (2020)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6baks66g6qe9j5c4o25q5dfub2